Abstract
Gene delivery in cystic fibrosis is hampered by extracellular and intracellular biological barriers and inefficient vectors. Although progress is evident, continued bioengineering of DNA, vectors, and delivery technologies will be critical to ensure biocompatibility, safety, and therapeutic effectiveness. Both viral and nonviral vectors demonstrate insufficient gene expression to adequately correct chloride ion and respiratory homeostasis, but vector modifications and novel vector types continue to advance understanding of transfection processes, immunobiological responses, and cystic fibrosis pathology. Interactions of toll-like receptors and other coreceptors may be critical components of cystic fibrosis immunobiology but additional research will be needed before causative associations are widely established; however, receptor modulation provides a theoretical framework to develop new therapeutic approaches. Clinical-phase pharmacotherapies offer short-term promise to restore electrolyte imbalance and/or symptomatology, but it may be many years before gene therapy offers a curative solution for the disease.
Keywords: Cystic fibrosis, gene therapy, viral vectors, nonviral vectors, transfection, toll-like receptors, progress
Current Gene Therapy
Title: Cystic Fibrosis, Vector-Mediated Gene Therapy, and Relevance of Toll-Like Receptors: A Review of Problems, Progress, and Possibilities
Volume: 8 Issue: 3
Author(s): Timothy J. Atkinson
Affiliation:
Keywords: Cystic fibrosis, gene therapy, viral vectors, nonviral vectors, transfection, toll-like receptors, progress
Abstract: Gene delivery in cystic fibrosis is hampered by extracellular and intracellular biological barriers and inefficient vectors. Although progress is evident, continued bioengineering of DNA, vectors, and delivery technologies will be critical to ensure biocompatibility, safety, and therapeutic effectiveness. Both viral and nonviral vectors demonstrate insufficient gene expression to adequately correct chloride ion and respiratory homeostasis, but vector modifications and novel vector types continue to advance understanding of transfection processes, immunobiological responses, and cystic fibrosis pathology. Interactions of toll-like receptors and other coreceptors may be critical components of cystic fibrosis immunobiology but additional research will be needed before causative associations are widely established; however, receptor modulation provides a theoretical framework to develop new therapeutic approaches. Clinical-phase pharmacotherapies offer short-term promise to restore electrolyte imbalance and/or symptomatology, but it may be many years before gene therapy offers a curative solution for the disease.
Export Options
About this article
Cite this article as:
Atkinson J. Timothy, Cystic Fibrosis, Vector-Mediated Gene Therapy, and Relevance of Toll-Like Receptors: A Review of Problems, Progress, and Possibilities, Current Gene Therapy 2008; 8 (3) . https://dx.doi.org/10.2174/156652308784746468
DOI https://dx.doi.org/10.2174/156652308784746468 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
Current Cancer Drug Targets Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis
Current Chemical Biology Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery
Current Pharmaceutical Design Meet Our Editor
Current Gene Therapy Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Current Drug Targets Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry Nanomedicine for Cancer Therapy Using Autophagy: An Overview
Current Topics in Medicinal Chemistry Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets Runx1/AML1 is a Guardian of Hematopoietic Stem Cells
Current Cancer Therapy Reviews Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets Combinatorial Synthesis and Characterization of New Asymmetric Porphyrins as Potential Photosensitizers in Photodynamic Therapy
Combinatorial Chemistry & High Throughput Screening Lung Cancer Brachytherapy
Current Cancer Therapy Reviews Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Radiolabeled Nanoparticles, Angionesis and Therapeutics of Cancer Researches Together With Preclinical Models
Current Radiopharmaceuticals Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry